{"entity":{"id":"rem-422","kind":"drug","name":"REM-422","aka":[],"tldr":"REM-422 is a small-molecule inhibitor from Remix Therapeutics, in registered phase 2 trials for salivary gland cancers.","summary":"REM-422 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Remix Therapeutics, in salivary gland cancers. Described in the registry record as a small molecule mrna inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of REM-422","url":"https://clinicaltrials.gov/search?intr=REM-422"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["salivary-gland"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06118086"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"REM-422","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a small molecule mrna inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rem-422/","neighbours":{"cancer":[{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"}],"trial":[{"id":"nct06118086","kind":"trial","name":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","route":"/trials/nct06118086/"}]}}